^
Association details:
| Biomarker: | FGFR2 fusion |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Taiho Pharmaceutical Obtains Approval in Japan to Manufacture and Market FGFR Inhibitor LYTGOBI® Tablets 4mg for Unresectable Biliary Tract Cancer Harboring FGFR2 Gene Fusions That Has Progressed After Chemotherapy
Published date:
06/26/2023
Excerpt:
Taiho Pharmaceutical...announced today that it has been granted approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market the FGFR inhibitor “LYTGOBI® tablets 4mg” (generic name: futibatinib) for unresectable biliary tract cancer harboring FGFR2 gene fusions that has progressed after chemotherapy.
